The nation of Zimbabwe has turned down a substantial American health deal worth $367m (£272m) over five years over Washington's insistence on confidential biological samples.
The decision was revealed after a government memo from December was leaked, which showed Head of State Emmerson Mnangagwa believed the agreement was "skewed".
A government spokesperson later stated that the US was demanding access to biological samples for research and profit while was not willing to share the resulting advantages from any future medical innovations.
"We must now begin the difficult and regrettable process of scaling back our health assistance in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had furnished more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for more negotiations to find a deal acceptable to all parties so the nation's critical HIV treatment initiative can be sustained.
Wider Background
This rejection follows a similar case in Kenya, where a court suspended a similar deal with the US following legal challenges were filed about the safety of Kenyans' health data.
Since resuming the presidency last year, US President Donald Trump has drastically cut foreign aid and shut down the US Agency for International Development (USAID).
The agency had managed aid for the US government, but Trump argued its spending was "wasteful" and his government was seeking government-to-government deals to boost openness and accountability.
According to reports, Sixteen African countries have to date agreed to these new agreements, constituting over $18.3bn of fresh investment.
Specifics of the Declined Deal
The funds for Zimbabwe was intended to funded "HIV/Aids treatment and prevention, tuberculosis, malaria, healthcare for mothers and children, and disease outbreak preparedness.
"We are confident this partnership might have yielded significant benefits for Zimbabwean communities, especially the 1.2 million currently receiving antiretroviral therapy through American-funded programmes," the Ambassador added.
However, official spokesman Nick Mangwana maintained the arrangement was "asymmetrical".
"Our nation was requested to provide its genetic material and health information for a long time, with no equivalent guarantee of access to any scientific breakthroughs – such as new medicines or tests – that might result from that shared data," his statement read.
"In essence, our country would provide the raw materials for scientific discovery without any certainty that the end products would be available to our people if a new disease outbreak emerge."
National Interest and Global Health
He also noted that the US's withdrawal from the global health body and its pursuit of one-on-one health agreements were undermining frameworks already established via the international health agency.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework created to deal with future global health emergencies.
"This framework is designed to guarantee that when a country provides its information, the benefits – including vaccines and treatments – are distributed fairly, not commercialised solely by those with the capability to create them."
The government's concerns regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We encourage further discussions with our American counterparts on how subsequent collaboration could be arranged in a manner that respects the independence and interests of each country."
Medical Community Reaction
Medical experts said it understood the official position, but urged that negotiations need to persist considering a large portion of the country's Aids initiatives were funded by foreign aid.
"Where specific concerns arise, such as those involving data governance or agreement terms, these can frequently be resolved via technical clarification and mutually agreed protections," it commented.
This impasse underscores the ongoing debate between accepting crucial foreign assistance and safeguarding local interests in an ever more data-driven world.